Vyxeos liposomal inj.

Ingredient

Each vial contains 44 mg of daunorubicin and 100 mg of cytarabine

Content

Powder for concentrate for solution for infusion.
Purple, lyophilised cake.

Indication

Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute
myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)